Relation entre consommation de benzodiazépines et chutes en gériatrie : étude multicentrique dans trois établissements gériatriques d’un CHU

Uhart, M.; Odouard, Emmanuel; Carlier, C. Mahé-Le; Maire, Pascal; Ducher, Michel; Bourguignon, Laurent

doi:10.1016/j.pharma.2011.10.002

Cited by 8 publications

(3 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…En cuanto a los efectos físicos colaterales producidos por el consumo de BZD se ha asociado su prescripción a accidentes de tráfico en carretera, caídas y fractura de cadera, donde han demostrado que quienes consumen BZD son más propensos a participar de alguno de estos episodios, debido a lo afectadas que se ven habilidades cognitivas complejas como la conducción y la coordinación motriz (Airagnes et al, 2016;Flores, 2016;Formiga et al, 2012;Lader, 2014). Por otro lado, se encontró que son las mujeres de edad avanzada quienes sufren mayores efectos físicos colaterales por el uso de estos medicamentos, siendo el bromazepam la BZD más consumida e influyente en ello, aumentando considerablemente el porcentaje de caídas recurrentes y lesiones por caídas (Rossat et al, 2011;Uhart et al, 2012;Danza et al, 2015;Softic, Beganlic, Pranjic, y Sulejmanovic, 2013). Contrario al estudio anterior, una investigación realizada en Canadá (Sylvestre, Abrahamowicz, Čapek, y Tamblyn, 2011) no encontró asociaciones significativas entre el riesgo de sufrir lesiones por caídas y el clordiazepóxido, lorazepam y bromazepam, a pesar de ser lorazepam la BZD más consumida.…”

Section: Efectos Colaterales Del Uso De Benzodiacepinasunclassified

“…Debido a esto, conocer los efectos provocados por las BZD más allá de los farmacológicos es cada vez más relevante. Algunos efectos conocidos provocados por su uso en AM son: deterioro cognitivo (Florián y Buitrago, 2013;Islam et al, 2016), rendimiento psicomotor (Danza et al, 2015;Uhart et al, 2012), dependencia (Nkogho Mengue, Abdous, Berbiche, Préville, y Voyer, 2013;Minaya, Ugalde, y Fresán, 2009), entre otras. El primer acercamiento a las BZD suele ser por prescripción médica, a diferencias de otras drogas sean legales o ilegales.…”

Section: Introductionunclassified

See 1 more Smart Citation

Efectos negativos del uso de benzodiacepinas en adultos mayores: Una breve revisión

et al. 2019

View full text Add to dashboard Cite

Introduction: One part of polypharmacy is related to different medical conditions that come with age in senior patients. Whether they are adequately prescribed or not, most pharmaceutical compounds may potentially produce negative effects in consumers. One of the most highly prescribed psychopharmaceutics in seniors is benzodiazepine. This drug, usually prescribed to treat insomnia or anxiety, is said to be potentially risky for patients' health. Objective: To determine the existence of scientific evidence of benzodiazepine negative effects in seniors. Method: Scientific publications from 2007 through to 2017 were systematically consulted. The database was Scielo, Pubmed, Redalyc, Ebscohost, and Google Scholar. Keywords for the search included seniors, benzodiazepines, physical and psychological effects, psychopharmaceutics, both in English and Spanish. Findings: The most highly consumed benzodiazepine by seniors is Diazepam. Anxiety and insomnia are among the most frequent reasons for its prescription. Regarding negative effects, this drug is highly addictive. Side effects include a high probability of falling, leaving bone fractures as a result, decline of cognitive abilities, and a paradoxical increase of the symptoms for which it was originally prescribed. Senior consumers of benzodiazepine are more frequently female.

show abstract

Section: Efectos Colaterales Del Uso De Benzodiacepinasunclassified

Section: Introductionunclassified

Efectos negativos del uso de benzodiacepinas en adultos mayores: Una breve revisión

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The consequences of BZDR are multiple with an increased risk of daytime sedation, balance disorders leading to falls and fractures, cognitive disorders, road accidents and dementia (1,2). Also, given their comorbidities, physiological changes, and multiple medications, the older adults are more at risk of experiencing from BZDR adverse events, like falls, driving accidents, dementia or even death (5)(6)(7)(8)(9). The majority of patients are unaware of these potential risks and continue to use these medications over the long term.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of the effectiveness of a joint general practitioner-pharmacist intervention on the implementation of benzodiazepine deprescribing in older adults (BESTOPH-MG trial): protocol for a cluster-randomized controlled trial

Huon,

Nizet,

Caillet

et al. 2023

Front. Med.

View full text Add to dashboard Cite

BackgroundDeprescribing benzodiazepines and related drugs (BZDR) is a challenge due to a lack of time on physicians’ part, a lack of involvement of other health professionals, and the need for adapted tools. This study is based on primary care collaboration, by evaluating the effectiveness of a joint intervention between general practitioners and community pharmacists on the implementation of BZDR deprescribing in older adults.MethodsThis is a cluster randomized controlled trial in which each cluster will be formed by a physician-pharmacist pair. Within a cluster allocated to the intervention, the pharmacist will be trained in motivational interviewing (MI), and will offer the patient 3 interviews after inclusion by the physician. They will base their intervention on validated deprescribing guidelines. The pharmacist will receive methodological support during the first interviews. Interprofessional collaboration will be encouraged by writing reports for the physician after each interview. The following implementation outcomes will be evaluated: acceptability/adoption, appropriateness, cost, and fidelity. They will be measured by means of sociological interviews, observations, logbooks, and cost-utility analysis. Focus groups with physicians and pharmacists will be carried out to identify levers and barriers experienced in this collaboration. Observations will be conducted with pharmacists to assess their approach of the MIs. Effectiveness outcomes will be based on medication (discontinuation or reduction of BZDR) and clinical outcomes (such as quality of life, insomnia or anxiety), assessed by health insurance databases and validated questionnaires.DiscussionThis study will determine whether collaboration in primary care between physicians and pharmacists, as well as training and coaching of pharmacists in motivational interviewing, allows the implementation of BZDR deprescribing in the older adults.This study will provide an understanding of the processes used to implement deprescribing guidelines, and the contribution of collaborative practice in implementing BZDR discontinuation. The cluster methodology will allow to assess the experience of the relationship between the different primary care actors, and the related obstacles and levers.The results obtained will make it possible to produce guidelines on the involvement of community pharmacists in the management of substance abuse in older adults, or even to legislate new missions or care pathways.Clinical trial registrationClinicalTrials.gov, identifier, NCT05765656.

show abstract

Individualizing Drug Therapy in the Elderly

Maire¹,

Bourguignon²,

Goutelle³

et al. 2017

Individualized Drug Therapy for Patients

View full text Add to dashboard Cite

Relation entre consommation de benzodiazépines et chutes en gériatrie : étude multicentrique dans trois établissements gériatriques d’un CHU

Cited by 8 publications

References 32 publications

Efectos negativos del uso de benzodiacepinas en adultos mayores: Una breve revisión

Efectos negativos del uso de benzodiacepinas en adultos mayores: Una breve revisión

Evaluation of the effectiveness of a joint general practitioner-pharmacist intervention on the implementation of benzodiazepine deprescribing in older adults (BESTOPH-MG trial): protocol for a cluster-randomized controlled trial

Individualizing Drug Therapy in the Elderly

Contact Info

Product

Resources

About